Key facts
- It has raised $5.0M; the latest was Early Stage VC ($5.0M) in Aug 2025.
- Notable investors include Rollman Management, Synergy Media UG.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pharmatech AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Pharmatech AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pharmatech AI
Developer of an AI-based drug discovery platform designed for the acceleration and optimization of pharmaceutical research and development. The company's platform uses advanced graph neural networks and transformer models to predict millions of molecular interactions, includes detailed analysis of cannabis-related compounds, and runs on a fully integrated research setup with its own lab and sustainable energy system, enabling pharmaceutical teams to discover better treatments faster, with fewer costs and less trial-and-error.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Website
- pharmatech-ai.com/
- Ownership
- Privately Held (backing)
Pharmatech AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharmatech AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharmatech AI in its N-PORT filings yet. We sweep new filings monthly.